A survey of new Rx, new generic, and new OTC products
FDA Approves Dupilumab for Treatment of Chronic Spontaneous Urticaria
The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.
The Current, Future Roles of AI within the Pharmacy Profession
As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.
FDA Grants Yuflyma Interchangeability Designation for Humira
The FDA approved adalimumab-aaty in May 2023 for 8 indications, including rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.
The Unique Challenges, Growth in the Business of Health-System Pharmacy
From market pressures to regulatory framework, Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed growth in the business of health-system pharmacy and the challenges it has faced.
FDA Grants Fast Track Designation for Potential Bird Flu Vaccine
The designation addresses the unmet need for prevention of H5N1, which remains a global health risk, and a phase 1 trial of the vaccine was initiated in November 2024.
FDA Approves Generic Liraglutide for Type 2 Diabetes
As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.
